The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 30, 2020

Filed:

Jan. 26, 2017
Applicant:

The Johns Hopkins University, Baltimore, MD (US);

Inventors:

Gyanu Lamichhane, Towson, MD (US);

Craig A. Townsend, Baltimore, MD (US);

Evan Lloyd, Bunker Hill, WV (US);

Amit Kaushik, Baltimore, MD (US);

Pankaj Kumar, Baltimore, MD (US);

Joel Freundlich, Princeton, NJ (US);

Shaogang Li, Newark, NJ (US);

Sean Ekins, Fuquay Varina, NC (US);

Nicole Parrish, Bunker Hilol, WV (US);

Assignees:

The Johns Hopkins University, Baltimore, MD (US);

Rutgers, The State University of New Jersey, New Brunswick, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/407 (2006.01); A61P 31/04 (2006.01); A61K 31/431 (2006.01); A61K 45/06 (2006.01); C07D 477/00 (2006.01); C07D 499/897 (2006.01); C07D 477/20 (2006.01); C07D 499/893 (2006.01); A61K 31/427 (2006.01); A61K 31/496 (2006.01); A61K 31/546 (2006.01); A61K 31/43 (2006.01); A61K 31/4196 (2006.01);
U.S. Cl.
CPC ...
A61K 31/407 (2013.01); A61K 31/4196 (2013.01); A61K 31/427 (2013.01); A61K 31/43 (2013.01); A61K 31/431 (2013.01); A61K 31/496 (2013.01); A61K 31/546 (2013.01); A61K 45/06 (2013.01); A61P 31/04 (2018.01); C07D 477/00 (2013.01); C07D 477/20 (2013.01); C07D 499/893 (2013.01); C07D 499/897 (2013.01);
Abstract

New antimicrobials targeting L,D-transpeptidases, non-classical cysteine peptidases, have been developed and their unique chemical structures identified. Carbapenems and penems of the present invention are unique among β-lactams as they acylate and inhibit L,D-transpeptidases, which likely results in their superior antimicrobial potency. These new antimicrobial agents can be used alone, or in combination with other classic antimicrobial agents that target D,D transpeptidases, when treating bacterial infections.


Find Patent Forward Citations

Loading…